10-QPeriod: Q1 FY2020

CME GROUP INC. Quarterly Report for Q1 Ended Mar 31, 2020

Filed May 6, 2020For Securities:CME

Summary

CME Group Inc. reported robust financial results for the first quarter of 2020, driven by a significant surge in trading volumes across various asset classes. Total revenues increased by 29% year-over-year to $1.52 billion, primarily fueled by a 34% jump in clearing and transaction fees to $1.28 billion. This growth was largely attributed to heightened market volatility stemming from the COVID-19 pandemic, which spurred increased trading activity in interest rates, equity indexes, energy, and metals. Net income attributable to CME Group surged by 54% to $766.2 million, with diluted earnings per share rising to $2.14 from $1.39 in the prior year period. The company's operational efficiency also improved, with operating margin expanding to 63.1%. Despite increased expenses, notably in licensing and other fee agreements and asset impairments, the strong revenue growth outpaced cost increases. CME Group maintained a strong liquidity position and continued to manage its debt effectively, ending the quarter with $0.9 billion in cash and cash equivalents. The company also highlighted its preparedness for market disruptions, reinforcing its robust risk management framework and regulatory compliance.

Financial Statements
Beta
Revenue$1.52B
Operating Expenses$562.20M
Operating Income$959.90M
Net Income$766.20M
EPS (Basic)$2.14
EPS (Diluted)$2.14
Shares Outstanding (Basic)357.52M
Shares Outstanding (Diluted)358.45M

Key Highlights

  • 1Total revenues increased 29% to $1.52 billion in Q1 2020 compared to Q1 2019.
  • 2Net income attributable to CME Group increased 54% to $766.2 million.
  • 3Diluted earnings per share rose to $2.14 from $1.39 in the prior year period.
  • 4Clearing and transaction fees grew by 34% to $1.28 billion, driven by a 47% increase in total contract volume.
  • 5Significant volume growth was observed across interest rates (34%), equity indexes (106%), energy (38%), and metals (58%), fueled by market volatility related to COVID-19.
  • 6Operating margin improved to 63.1% from 53.5%.
  • 7Cash flows from operating activities increased 13% to $757.1 million.

Frequently Asked Questions

The primary driver of CME Group's revenue growth was a significant increase in clearing and transaction fees, which rose by 34% to $1.28 billion. This was directly attributable to a 47% surge in total contract volume, fueled by heightened market volatility and economic uncertainty caused by the COVID-19 pandemic across various asset classes.

The COVID-19 pandemic led to increased market volatility, which, in turn, drove significant increases in trading volumes across interest rates, equity indexes, energy, and metals. This volatility boosted clearing and transaction fees and overall revenues. CME Group also closed its open outcry trading floors and transitioned to fully electronic trading, demonstrating operational resilience. While some expenses increased due to impairments and licensing fees, the revenue growth substantially offset these costs, leading to a strong increase in net income and EPS.

As of March 31, 2020, CME Group had $851.7 million in cash and cash equivalents. The company's total long-term debt stood at $3.54 billion. CME Group maintained significant borrowing capacity under its revolving credit facilities, with approximately $2.3 billion available under its multi-currency revolving senior credit facility. The company was in compliance with all financial covenant requirements.

The company's performance is closely tied to market volatility and trading volumes. Given the ongoing economic uncertainties and potential for continued market fluctuations, CME Group is well-positioned to benefit from increased activity. While market data and information services revenue remained relatively flat, the core clearing and transaction fees are expected to remain strong as long as volatility persists. The company continues to manage its product mix and pricing strategies to optimize revenue per contract.